Zogenix Acquires U.K.-Based Brabant Pharma
October 27, 2014Zogenix acquires Brabant Pharma (a U.K.-based pharmaceutical company) and gains rights to global development and commercialization of Brabafen™ for the treatment of Dravet syndrome. Zogenix will initiate Phase 3 clinical trials of Brabafen™ in Q2 2015.
More »
Clovis Oncology Announces First Patient Enrolled in Lucitanib Phase 2 Study in Squamous Non-small Cell Lung Cancer
October 23, 2014Clovis Oncology began its global Phase 2 study of lucitanib, a unique tyrosine kinase inhibitor, for treatment of patients with FGFR1-amplified squamous non-small cell lung cancer and the first patients has been dosed in the U.S.
More »
Five Prime Therapeutics Announces Expansion of Respiratory Disease Research Collaboration and License Agreement With GSK
October 23, 2014Five Prime expands its respiratory disease research collaboration with GSK, first established in 2012. This collaboration increased to include two drug discovery programs for respiratory diseases for 18 additional months.
More »